Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWilliams, K.en
dc.contributor.authorAhn, K.en
dc.contributor.authorChen, M.en
dc.contributor.authorAljurf, M.en
dc.contributor.authorAgwu, A.en
dc.contributor.authorChen, A.en
dc.contributor.authorWalsh, T.en
dc.contributor.authorSzabolcs, P.en
dc.contributor.authorBoeckh, M.en
dc.contributor.authorAuletta, J.en
dc.contributor.authorLindemans, C.en
dc.contributor.authorZanis-Neto, J.en
dc.contributor.authorMalvezzi, M.en
dc.contributor.authorLister, J.en
dc.contributor.authorDe Toledo Codina, J.en
dc.contributor.authorSackey, K.en
dc.contributor.authorChakrabarty, J.en
dc.contributor.authorLjungman, P.en
dc.contributor.authorWingard, J.en
dc.contributor.authorSeftel, M.en
dc.contributor.authoret al.en
dc.identifier.citationBone Marrow Transplantation, 2016; 51(4):573-580en
dc.descriptionPublished online 4 January 2016en
dc.description.abstractPneumocystis jiroveci pneumonia (PJP) is associated with high morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Little is known about PJP infections after HSCT because of the rarity of disease given routine prophylaxis. We report the results of a Center for International Blood and Marrow Transplant Research study evaluating the incidence, timing, prophylaxis agents, risk factors and mortality of PJP after autologous (auto) and allogeneic (allo) HSCT. Between 1995 and 2005, 0.63% allo recipients and 0.28% auto recipients of first HSCT developed PJP. Cases occurred as early as 30 days to beyond a year after allo HSCT. A nested case cohort analysis with supplemental data (n=68 allo cases, n=111 allo controls) revealed that risk factors for PJP infection included lymphopenia and mismatch after HSCT. After allo or auto HSCT, overall survival was significantly poorer among cases vs controls (P=0.0004). After controlling for significant variables, the proportional hazards model revealed that PJP cases were 6.87 times more likely to die vs matched controls (P<0.0001). We conclude PJP infection is rare after HSCT but is associated with high mortality. Factors associated with GVHD and with poor immune reconstitution are among the risk factors for PJP and suggest that protracted prophylaxis for PJP in high-risk HSCT recipients may improve outcomes.en
dc.description.statementofresponsibilityKM Williams ...A Yong ... et al.en
dc.publisherNature Publishing Groupen
dc.rights© 2016 Macmillan Publishers Limited. All rights reserved.en
dc.subjectHumans; Pneumocystis carinii; Pneumonia, Pneumocystis; Hematopoietic Stem Cell Transplantation; Incidence; Risk Factors; Female; Male; Allografts; Autograftsen
dc.titleThe incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysisen
dc.typeJournal articleen
pubs.library.collectionPathology publicationsen
dc.identifier.orcidYong, A. [0000-0001-9452-1533]en
Appears in Collections:Pathology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.